News Release

June 2008

March 2008

February 2008

October 16, 2007, Blaine, Washington

Patrick Murphy joins Advisory Board

Diversified Bio-Medics, Inc. (DBMI) a Nevada corporation with a focus on the development of cGMP facilities for biomanufacturing, is pleased to announce the appointment of Mr. Patrick Murphy to the position on the  Advisory Board of DBMI with a focus on operations and corporate development.

Patrick Murphy is Vice President of Operations at Solstice Neurosciences, Inc. with global headquarters located in Malvern, Pennsylvania, and Manufacturing and Customer Support located in South San Francisco, California. Solstice is a specialty biopharmaceutical company focused on the development, manufacturing, sales and marketing of toxins. Solstice’s first approved product, Myobloc® Injectable Solution (also know as NeuroBloc® in Europe) represents the only botulinum toxin type B currently available to physicians and patients worldwide. At Solstice, Patrick is responsible for Manufacturing, quality assurance, quality control, facilities, materials management, production planning, technical operations and engineering.

Prior to joining Solstice Neurosciences, Patrick worked at Acologix, Inc, as Vice President of CMC and Operations. Acologix is a biology-based biopharmaceutical company focusing on the identification and development of novel therapeutics for major unmet medical needs. Acologix strives to improve patients’ lives by developing and commercializing innovative biopharmaceuticals targeting “osteo-renal” (bone and kidney) diseases. His responsibilities included contract manufacturing, quality assurance, quality control, pharmaceutical development and operations.

Prior to joining Acologix, Patrick worked at Abgenix, Inc. for 5 years, most recently as Senior Vice President of Production Services. His responsibilities included manufacturing, contract manufacturing, process sciences, quality assurance, quality control, materials management, purchasing and other support functions. As Vice President of Manufacturing, he was responsible for manufacturing, contract manufacturing, engineering, facilities, environmental health and safety, security, materials management, logistics, purchasing and office management. Abgenix is a biopharmaceutical company focused on the development and commercialization of human therapeutic antibodies.

Prior to joining Abgenix, Patrick worked at Genentech, Inc. for nearly 19 years. During that time, he held various positions including Director of Strategic Operations and Director of Biochemical Manufacturing. Patrick played a key role in the development and commercialization of numerous molecules as well as in the design, construction, start up and subsequent approval of many facility projects. He has extensive experience in process scale up, technology transfer and modeling.

Prior to joining Genentech, Patrick worked at Dynapol, Inc. for 5 years. During that time, he held various positions in manufacturing and process development. Dynapol developed and manufactured polymeric food dyes and polymeric antioxidants for use in foods.

Patrick received a BS degree in Biochemistry from the State University of New York at Binghamton in 1976.